Anifrolumab (Saphnelo)

Abstract


 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses anifrolumab for IV injection solution, 150 mg/mL.
 Indication: In addition to standard therapy for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus.